PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model.
暂无分享,去创建一个
[1] Gang Wang,et al. Mutual enhancement between heparanase and vascular endothelial growth factor: a novel mechanism for melanoma progression. , 2011, Cancer letters.
[2] A. Jemal,et al. Cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.
[3] C. L. Chu,et al. M402, a Novel Heparan Sulfate Mimetic, Targets Multiple Pathways Implicated in Tumor Progression and Metastasis , 2011, PloS one.
[4] G. Sledge,et al. Rethinking the metastatic cascade as a therapeutic target , 2011, Nature Reviews Clinical Oncology.
[5] P. Carmeliet,et al. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? , 2011, Nature Reviews Clinical Oncology.
[6] Jiannis Ragoussis,et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization , 2011, Nature Medicine.
[7] L. Borsig,et al. Sulfated hexasaccharides attenuate metastasis by inhibition of P-selectin and heparanase. , 2011, Neoplasia.
[8] Robert S. Kerbel,et al. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis , 2011, Nature Reviews Clinical Oncology.
[9] T. Gonda,et al. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models , 2011, British Journal of Cancer.
[10] P. Gunaratne,et al. MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. , 2011, Cancer research.
[11] F. Zunino,et al. SST0001, a Chemically Modified Heparin, Inhibits Myeloma Growth and Angiogenesis via Disruption of the Heparanase/Syndecan-1 Axis , 2011, Clinical Cancer Research.
[12] Neha S. Gandhi,et al. Heparin/heparan sulphate-based drugs. , 2010, Drug discovery today.
[13] R. Sanderson,et al. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis , 2010, The FEBS journal.
[14] T. Gonda,et al. The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy , 2010, Investigational New Drugs.
[15] A. Balmain,et al. Guidelines for the welfare and use of animals in cancer research , 2010, British Journal of Cancer.
[16] J. Sleeman,et al. Cancer metastasis as a therapeutic target. , 2010, European journal of cancer.
[17] Y. Hitoshi,et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. , 2010, Cancer research.
[18] R. Kerbel,et al. Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy , 2009, Clinical Cancer Research.
[19] K. Hunter,et al. Preclinical Drug Development Must Consider the Impact on Metastasis , 2009, Clinical Cancer Research.
[20] Qin Chen,et al. Marine-derived oligosaccharide sulfate (JG3) suppresses heparanase-driven cell adhesion events in heparanase over-expressing CHO-K1 cells , 2009, Acta Pharmacologica Sinica.
[21] Bob van de Water,et al. An improved model to study tumor cell autonomous metastasis programs using MTLn3 cells and the Rag2−/− γc−/− mouse , 2009, Clinical & Experimental Metastasis.
[22] L. Jeng,et al. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. , 2009, Journal of hepatology.
[23] Masahiro Inoue,et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.
[24] John M L Ebos,et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.
[25] Stephen E. Jones. Metastatic breast cancer: the treatment challenge. , 2008, Clinical breast cancer.
[26] D. Sargent,et al. Assessing the measure of a new drug: is survival the only thing that matters? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] I. Vlodavsky,et al. Heparanase induces Akt phosphorylation via a lipid raft receptor. , 2007, Biochemical and biophysical research communications.
[28] L. Martins,et al. Heparanase expression in circulating lymphocytes of breast cancer patients depends on the presence of the primary tumor and/or systemic metastasis. , 2007, Neoplasia.
[29] E. Mckenzie,et al. Heparanase: a target for drug discovery in cancer and inflammation , 2007, British journal of pharmacology.
[30] M. Götte,et al. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. , 2006, Cancer research.
[31] R. Sasisekharan,et al. The Impact of Heparanese and Heparin on Cancer Metastasis and Angiogenesis , 2006, Pathophysiology of Haemostasis and Thrombosis.
[32] T. Peretz,et al. Heparanase promotes growth, angiogenesis and survival of primary breast tumors , 2006, International journal of cancer.
[33] I. Vlodavsky,et al. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. , 2006, Cancer research.
[34] M. Nakajima,et al. COX-2 induction by heparanase in the progression of breast cancer. , 2006, International journal of molecular medicine.
[35] L. Khachigian,et al. Early Growth Response Gene 1 (EGR1) Regulates Heparanase Gene Transcription in Tumor Cells* , 2005, Journal of Biological Chemistry.
[36] J. O’Shaughnessy. Extending survival with chemotherapy in metastatic breast cancer. , 2005, The oncologist.
[37] P. Gattuso,et al. Ductal carcinoma in situ of the breast and heparanase-1 expression: a molecular explanation for more aggressive subtypes. , 2005, Journal of the American College of Surgeons.
[38] L. Khachigian,et al. Regulation of Inducible Heparanase Gene Transcription in Activated T Cells by Early Growth Response 1* , 2003, Journal of Biological Chemistry.
[39] P. Gattuso,et al. Heparanase-1 expression is associated with the metastatic potential of breast cancer. , 2002, Surgery.
[40] I. Pecker,et al. The FASEB Journal express article 10.1096/fj.00-0895fje. Published online May 29, 2001. , 2022 .
[41] J. Platt,et al. Heparanase, a potential regulator of cell-matrix interactions. , 2000, Trends in biochemical sciences.
[42] T. Martin,et al. A novel orthotopic model of breast cancer metastasis to bone , 1999, Clinical & Experimental Metastasis.
[43] T. Tsuruo,et al. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer. , 1996, Cancer research.
[44] Chi-Ping Day,et al. Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin , 2012, International journal of cancer.
[45] J. Mackey,et al. In the end what matters most? A review of clinical endpoints in advanced breast cancer. , 2011, The oncologist.
[46] Karthik Raman,et al. Chemical Tumor Biology of Heparan Sulfate Proteoglycans. , 2010, Current chemical biology.
[47] Matthew J Hayat,et al. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. , 2007, The oncologist.
[48] Vito Ferro,et al. Heparanase as a Target for Anticancer Therapeutics: New Developments and Future Prospects , 2006 .
[49] G. Hortobagyi,et al. Neoplasms of the Breast , 2003 .
[50] Research Paper Mediators of Inflammation, 10, 259–267 (2001) , 2022 .